The Respiratory Syncytial Virus market growth is driven by factors like increase in the prevalence of Respiratory Syncytial Virus, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Respiratory Syncytial Virus market report also offers comprehensive insights into the Respiratory Syncytial Virus market size, share, Respiratory Syncytial Virus epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Respiratory Syncytial Virus market size growth forward.
Some of the key highlights from the Respiratory Syncytial Virus Market Insights Report:
- Several key pharmaceutical companies, including Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and others, are developing novel products to improve the Respiratory Syncytial Virus treatment outlook.
- The total Respiratory Syncytial Virus market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Respiratory Syncytial Virus market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Respiratory Syncytial Virus Market Landscape
Respiratory Syncytial Virus Overview
Respiratory Syncytial Virus is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. Respiratory Syncytial Virus belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human Respiratory Syncytial Virus, bovine Respiratory Syncytial Virus, and murine pneumonia virus. Two major antigenic subtypes of human Respiratory Syncytial Virus (A and B) are determined mainly by antigenic drift and duplications in Respiratory Syncytial Virus-G sequences but accompanied by genome-wide sequence divergence, including within Respiratory Syncytial Virus-F. Signs and symptoms of Respiratory Syncytial Virus infection most commonly appears about 4-6 days after exposure to the virus. Respiratory Syncytial Virus usually causes mild cold-like signs and symptoms in adults and older children. Signs and symptoms of severe Respiratory Syncytial Virus infection in infants include rapid breathing, cough, poor feeding, irritability, and unusual tiredness.
Respiratory Syncytial Virus Diagnosis
Testing for Respiratory Syncytial Virus is often not needed. If it is required, several types of laboratory tests are used for diagnosis. The most commonly used is the rapid diagnostic test. This test looks for Respiratory Syncytial Virus antigens in nasal secretions. If the rapid test is negative, the doctor may order a virus culture of the secretions. The doctor may also choose a more sensitive test that uses genetic technology to detect the virus in the blood. Laboratory tests for Respiratory Syncytial Virus include rapid antigen detection tests (RADTs), direct fluorescent antibody (DFA), polymerase chain reaction (PCR), and viral cultures. Other tests include a blood test, chest x-rays, and pulse oximetry.
Respiratory Syncytial Virus Treatment
Supportive care is the mainstay of treatment for Respiratory Syncytial Virus bronchiolitis. Most infants can be managed at home, but those who are ill-appearing, dehydrated, have poor feeding or apnea, develop respiratory distress or require supplemental oxygen should be considered for hospitalization. The typical length of stay in the hospital ranges 3–7 days. Supportive care includes hydration (i.e., oral or intravenous), clearing nasal obstruction with saline nose drops, nasal bulb suction or deep suctioning in the hospital, and nutrition for the patient. Bronchodilators, corticosteroids, antibiotics, and others are also used to treat Respiratory Syncytial Virus.
Do you know the treatment paradigms for different countries? Download our Respiratory Syncytial Virus Market Sample Report
Recent Breakthroughs in the Respiratory Syncytial Virus Market
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine For The Prevention Of Respiratory Syncytial Virus (RSV) In Older Adults: Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
Respiratory Syncytial Virus Epidemiology Insights:
- In 2022, the total incident cases of Respiratory Syncytial Virus in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
- Total incident cases of Respiratory Syncytial Virus were highest in those below 5 years, followed by 65 years and above, and the least number of cases were found in the 5 to 64 years age group.
- The United States comprised ~58% of the total incident Respiratory Syncytial Virus cases in the 7MM in 2022.
- EU4, the UK, and Japan contributed ~30% and 12% to the total incident pool of Respiratory Syncytial Virus in 2022.
- In 2022, as per the severity of Respiratory Syncytial Virus infection in children, mild, moderate, and severe cases formed 70%, 27%, and 3% of the total incident cases of Respiratory Syncytial Virus in the US, respectively.
Respiratory Syncytial Virus Epidemiology Segmentation
DelveInsight’s Respiratory Syncytial Virus market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Respiratory Syncytial Virus historical patient pools and forecasted Respiratory Syncytial Virus patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Respiratory Syncytial Virus Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Respiratory Syncytial Virus Prevalence
- Age-Specific Respiratory Syncytial Virus Prevalence
- Gender-Specific Respiratory Syncytial Virus Prevalence
- Diagnosed and Treatable Cases of Respiratory Syncytial Virus
Visit for more @ Respiratory Syncytial Virus Epidemiological Insights
Respiratory Syncytial Virus Treatment Market
The Respiratory Syncytial Virus market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Respiratory Syncytial Virus market trends by analyzing the impact of current Respiratory Syncytial Virus therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Respiratory Syncytial Virus market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Respiratory Syncytial Virus market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Respiratory Syncytial Virus market in 7MM is expected to witness a major change in the study period 2019-2032.
Respiratory Syncytial Virus Therapy Assessment
SYNAGIS (palivizumab): Swedish Orphan Biovitrum AB (SOBI)
Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of Respiratory Syncytial Virus. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. In June 1998, SYNAGIS was approved to prevent serious lower respiratory tract disease caused by Respiratory Syncytial Virus in pediatric patients in the US.
Respiratory Syncytial ViruspreF (PF-06928316): Pfizer
Pfizer’s investigational Respiratory Syncytial Virus vaccine candidate, Respiratory Syncytial ViruspreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that Respiratory Syncytial Virus uses to attack human cells. In March 2022, Pfizer announced that its Respiratory Syncytial Virus vaccine candidate, PF-06928316 or Respiratory Syncytial ViruspreF, received BTD from the US FDA to prevent lower respiratory tract disease caused by Respiratory Syncytial Virus in individuals 60 years or older.
Respiratory Syncytial VirusPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
GSK3844766A contains a recombinant subunit pre-fusion Respiratory Syncytial Virus antigen combined with GSK’s proprietary AS01 adjuvant, which is also used in the company’s shingles vaccine. The drug has accepted regulatory submissions in Europe and Japan for older adults aged 60+. The Regulatory decision in the US is expected in the first half of 2023. US FDA has set a Prescription Drug User Fee Act action date of May 2023.
mRNA-1345: Moderna
The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna’s mRNA-1345 Respiratory Syncytial Virus vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. In August 2021, Moderna received the FDA’s FTD for the Respiratory Syncytial Virus vaccine (mRNA-1345) in adults older than 60.
Respiratory Syncytial Virus Key Companies
- Bavarian Nordic
- GlaxoSmithKline
- Janssen
- Sanofi
- AstraZeneca
- Moderna
- ReViral
- Pfizer
For more information, visit Respiratory Syncytial Virus Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Respiratory Syncytial Virus Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Respiratory Syncytial Virus, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Respiratory Syncytial Virus epidemiology in the 7MM
- Respiratory Syncytial Virus marketed and emerging therapies
- Respiratory Syncytial Virus companies
- Respiratory Syncytial Virus market drivers and barriers
Key Questions Answered in the Respiratory Syncytial Virus Market Report 2032:
- What was the Respiratory Syncytial Virus market share distribution in 2019, and how would it appear in 2032?
- What is the total Respiratory Syncytial Virus market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Respiratory Syncytial Virus market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Respiratory Syncytial Virus market projected to expand at 7MM?
Table of Contents:
1 Respiratory Syncytial Virus Market Key Comprehensive Insights
2 Respiratory Syncytial Virus Market Report Introduction
3 Competitive Intelligence Analysis for Respiratory Syncytial Virus
4 Respiratory Syncytial Virus Market Analysis Overview at a Glance
5 Executive Summary of Respiratory Syncytial Virus
6 Respiratory Syncytial Virus Epidemiology and Market Methodology
7 Respiratory Syncytial Virus Epidemiology and Patient Population
8 Respiratory Syncytial Virus Patient Journey
9 Respiratory Syncytial Virus Treatment Algorithm, Respiratory Syncytial Virus Current Treatment, and Medical Practices
10 Key Endpoints in Respiratory Syncytial Virus Clinical Trials
11 Respiratory Syncytial Virus Marketed Therapies
12 Respiratory Syncytial Virus Emerging Therapies
13 Respiratory Syncytial Virus: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Respiratory Syncytial Virus
16 Respiratory Syncytial Virus Market Key Opinion Leaders Reviews
18 Respiratory Syncytial Virus Market Drivers
19 Respiratory Syncytial Virus Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Respiratory Syncytial Virus Epidemiology 2032
DelveInsight’s “Respiratory Syncytial Virus – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Respiratory Syncytial Virus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Respiratory Syncytial Virus Pipeline 2023
“Respiratory Syncytial Virus Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Respiratory Syncytial Virus market. A detailed picture of the Respiratory Syncytial Virus pipeline landscape is provided, which includes the disease overview and Respiratory Syncytial Virus treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/